Marker Therapeutics Inc — Liquidità (NASDAQ:MRKR) | MetaTrader

Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Flusso di cassa derivante dalle attività operative -18.86 M-27.28 M-26.97 M-16.44 M-10.91 M-12.01 M -12.01 M Flussi di cassa derivanti dalle attività di investimento -10.43 M-3.13 M-4.95 M18.66 M18.66 M— — Liquidità derivante dalle attività di finanziamento 6.74 M52.56 M202.13 K1.11 M14.99 M9.86 M 9.86 M Liquidità libera -25.65 M-27.28 M-26.97 M-16.44 M-10.91 M-12.01 M -12.01 M

Notizie

H.C. Wainwright conferma il rating Buy su Marker Therapeutics

MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates

Profound Medical (PROF) Reports Q4 Loss, Misses Revenue Estimates

Marker Therapeutics fissa la data per l’assemblea annuale degli azionisti 2026

Marker Therapeutics sets date for 2026 annual shareholder meeting and proposal deadline

MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know

Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics

MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy?

5 Small Drug Stocks to Buy as Industry Recovery Picks Up

Marker Therapeutics mantiene il rating Buy da H.C. Wainwright

Marker Therapeutics stock maintains Buy rating at H.C. Wainwright

Brookline Capital alza il target di prezzo delle azioni Marker Therapeutics a $5,60